Canadá - inglês - Health Canada

merck canada inc - measles virus vaccine live attenuated (edmonston b strain); mumps virus vaccine live attenuated (jeryl lynn strain); rubella virus vaccine live attenuated (wistar ra27/3 strain); varicella-zoster virus vaccine live attenuated (oka/merck strain) - powder for solution - 3.00log10 tcid50; 4.30log10 tcid50; 3.00log10 tcid50; 3.99log10 pfu - measles virus vaccine live attenuated (edmonston b strain) 3.00log10 tcid50; mumps virus vaccine live attenuated (jeryl lynn strain) 4.30log10 tcid50; rubella virus vaccine live attenuated (wistar ra27/3 strain) 3.00log10 tcid50; varicella-zoster virus vaccine live attenuated (oka/merck strain) 3.99log10 pfu - vaccines

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - water for injections, quantity: 0.85 ml - diluent, not applicable - excipient ingredients: - this product approved for registration as an amendment to a product accepted for inclusion in the artg as 'currently supplied' at the commencement of the therapeutic goods act 1989. indications are held in artg paper records. (old code)

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

e. merck ltd -

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - indinavir sulfate 250mg equivalent to 200 mg indinavir;  ;   - capsule - 200 mg - active: indinavir sulfate 250mg equivalent to 200 mg indinavir     excipient: gelatin lactose magnesium stearate tekprint blue sb-6018 - indicated for the treatment of adults with hiv-1 infection. clinical studies demonstrated: · reduced risk of progression to an aids-defining illness or death · increased overall survival · durable reduction in serum viral rna · durable increase in cd4 cell counts

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - indinavir sulfate 416.3mg equivalent to 333 mg indinavir;  ;   - capsule - 333 mg - active: indinavir sulfate 416.3mg equivalent to 333 mg indinavir     excipient: gelatin lactose magnesium stearate

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - indinavir sulfate 500mg equivalent to 400 mg indinavir;  ;   - capsule - 400 mg - active: indinavir sulfate 500mg equivalent to 400 mg indinavir     excipient: gelatin lactose magnesium stearate tekprint green sb-4020 - indicated for the treatment of adults with hiv-1 infection. clinical studies demonstrated: · reduced risk of progression to an aids-defining illness or death · increased overall survival · durable reduction in serum viral rna · durable increase in cd4 cell counts

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - hepatitis b vaccine, rdna 10 µg/ml - suspension for injection - 10 mcg/ml - active: hepatitis b vaccine, rdna 10 µg/ml excipient: aluminium as amorphous aluminum hydroxyphosphate sulphate borax formaldehyde potassium thiocyanate sodium chloride water for injection - immunisation against infection caused by all known subtypes of hepatitis b virus. hbvaxpro should also prevent hepatitis d (caused by the delta virus) since hepatitis d does not occur in the absence of hepatitis b infection.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - hepatitis b vaccine, rdna 40 µg/ml - suspension for injection - 40 mcg/ml - active: hepatitis b vaccine, rdna 40 µg/ml excipient: aluminium as amorphous aluminum hydroxyphosphate sulphate borax formaldehyde potassium thiocyanate sodium chloride water for injection - immunisation against infection caused by all known subtypes of hepatitis b virus. hbvaxpro should also prevent hepatitis d (caused by the delta virus) since hepatitis d does not occur in the absence of hepatitis b infection.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - measles vaccine 1000 tcid50 (at end of expiry); mumps vaccine 12500 tcid50 (at end of expiry); rubella vaccine 1000 tcid50 (at end of expiry) - suspension for injection - active: measles vaccine 1000 tcid50 (at end of expiry) mumps vaccine 12500 tcid50 (at end of expiry) rubella vaccine 1000 tcid50 (at end of expiry) excipient: dibasic potassium phosphate dibasic sodium phosphate monohydrate eagle minimum essential medium gelatin medium 199 monobasic potassium phosphate monobasic sodium phosphate monohydrate monosodium glutamate neomycin phenolsulfonphthalein sodium bicarbonate sorbitol sucrose water for injection - m-m-r ii is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months of age or older.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - pneumococcal polysaccharide vaccine 50 µg/ml (25mcg/dose of each of 23 named pneumococcal polysaccharides) - solution for injection - active: pneumococcal polysaccharide vaccine 50 µg/ml (25mcg/dose of each of 23 named pneumococcal polysaccharides) excipient: phenol sodium chloride water for injection - pneumovax 23 is indicated for vaccination against pneumococcal disease caused by those pneumococcal types included in the vaccine.